Selected Original Psychedelic Research Published by Fluence Lead Trainers

By Ingmar Gorman, PhD

Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical PracticeFront. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246

Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., … & Feduccia, A. A. (2020). Posttraumatic growth after MDMA‐assisted psychotherapy for posttraumatic stress disorder. Journal of Traumatic Stress33(2), 161-170.

Winkler, P., Gorman, I., & Kočárová, R.(2016). Use of LSD by Mental Health Professionals. In Neuropathology of drug addictions and substance misuse (pp. 773-781). Academic Press.

Gorman, I., (2015) Drug-assisted Psychotherapy. In Ingersoll, R. E., & Rak, C. F. (2015). Psychopharmacology for Mental Health Professionals: An Integrative Approach. Nelson Education.

Fujáková, M., Páleníček, T., Brunovský, M.,Gorman, I., Tylš, F., Kubešová, A., … & Horáček, J. (2014). The effect of((−)-2-oxa-4-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY379268), anmGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosisPharmacology Biochemistry and Behavior122, 212-221.

Páleníček, T., Fujáková, M., Brunovský, M.,Horáček, J., Gorman, I., Balíková, M., … & Höschl, C. (2013). Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in ratsPsychopharmacology225(1), 75-93.

Páleníček, T., Fujáková, M., Brunovský, M.,Balíková, M., Horáček, J., Gorman, I., … & Krajča, V. (2011).Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokineticsNeuropsychobiology63(4), 202-218.

By Elizabeth Nielson, PhD

Nielson, E. M. Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current PracticeJournal of Humanistic Psychology. June 2021. doi:10.1177/00221678211021204

Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical PracticeFront. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246

Tai, S. J.,Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R. L., Winzer, R.,Richards, W. A., … & Malievskaia, E. (2021). Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical ResearchFrontiers in Psychiatry12, 27.

Nielson, E. M., May, D. G., Forcehimes, A. A.,& Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessionsFrontiers in Pharmacology9, 132.

Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist trainingJournal of Psychedelic Studies2(2), 64-73.

By Jeffrey Guss, MD

Agin-Liebes, G. I., Malone, T.,Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … & Ross, S.(2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166.

Sloshower, J., Guss, J., Krause, R., Wallace, R. M.,Williams, M. T., Reed, S., & Skinta, M. D. (2020). Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal of Contextual Behavioral Science, 15, 12-19.

Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S.K., Owens, L. T., Bossis, A. P., … & Ross, S. (2018). Individual experiences in four cancer patients following psilocybin-assisted psychotherapyFrontiers in Pharmacology, 9, 256.

Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist trainingJournal of Psychedelic Studies,2(2), 64-73.

Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N.,Terrana, S., Friedman, H. L., … & Ross, S. (2017). Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distressJournal of Humanistic Psychology, 57(5), 488-519.

Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S.,Devenot, N., Friedman, H. L., … & Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysisJournal of Humanistic Psychology, 57(4), 354-388.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone,T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.

By Alan K Davis, PhD

Davis, A. K., Barrett, F. S.,& Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 39-45.

Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic useJournal of Psychopharmacology, 33(9), 1088-1101.

Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M.W., & Jesse, R. (2019). Survey of subjective” God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMTPloSone, 14(4).

Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R.M., & Renn, E. (2018). The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumptionJournal of Psychopharmacology,32(7), 779-792.

Davis, A. K., & Rosenberg, H. (2017). Specific harm reduction strategies employed by 3, 4-methylenedioxymethamphetmine/ecstasy users in the United States and the United Kingdom. Drug Science, Policy and Law, 3, 2050324517711069.

Davis, A. K., & Rosenberg, H. (2016). Using the Theory of Planned Behavior to predict implementation of harm reduction strategies among MDMA/ecstasy users. Psychology of Addictive Behaviors, 30(4), 500.

Davis, A. K., Bonar, E. E., Ilgen, M. A., Walton, M. A.,Perron, B. E., & Chermack, S. T. (2016). Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatmentAddictive Behaviors, 63, 132-136.

Davis, A. K., & Rosenberg, H. (2014). The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational usersJournal of Psychoactive Drugs, 46(2), 154-161.

By Kelan Thomas, PhD

Thomas, K., & Malcolm, B.(2021). Adverse Effects. Handbook of Medical Hallucinogens, 414.

Thomas, K., Malcolm, B., & Lastra, D. (2017).Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disordersJournal of Psychoactive Drugs, 49(5), 446-455.

Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C.,Abbas, A. I., Hufeisen, S. J., … & Roth, B. L. (2009). Predicting new molecular targets for known drugsNature, 462(7270), 175-181.

Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J.Z., Crowe, M. S., & Matsumoto, R. R. (2016). Dextromethorphan: An update onits utility for neurological and neuropsychiatric disordersPharmacology & Therapeutics, 159, 1-22.

By Casey Paleos, PhD

Ross, S., Bossis, A., Guss, J.,Agin-Liebes, G., Malone, T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trialJournal of Psychopharmacology, 30(12), 1165-1180.

Paleos, C. A., & Ross, S. (2013). Ketamine: a light in the darknessMultidisciplinary Association for Psychedelic Studies Bulletin, Special Edition, Spring, 28-33.